John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)


Background and purposeInfection with the John Cunningham virus (JCV) is required for the development of progressive multifocal leukoencephalopathy, the feared complication of natalizumab treatment in multiple sclerosis patients. The JCV seroconversion rate seems higher in natalizumab treated patients than in the normal population, with an unknown cause. MethodsNatalizumab concentration was correlated to JCV antibody status and seroconversion in a large cohort of multiple sclerosis patients. ResultsOne hundred and thirty-five patients were included. No correlation was found between natalizumab concentration and JCV status, JCV seroconversion or JCV index. ConclusionsHigher natalizumab concentrations do not explain the increased JCV seroconversion rate in natalizumab treated patients
Original languageEnglish
Pages (from-to)1196-1199
Number of pages4
JournalEuropean journal of neurology
Issue number9
Publication statusPublished - 1 Sept 2017


  • JC virus
  • multiple sclerosis
  • natalizumab

Cite this